Targeting Oncostatin M and IL-6 Family in Retinal Diseases
Author Information
Author(s): Mori Tommaso, Nagaraj Nareshkumar Ragavachetty, Surico Pier Luigi, Zhou Wenjing, Parmar Uday Pratap Singh, D’Esposito Fabiana, Gagliano Caterina, Musa Mutali, Zeppieri Marco
Primary Institution: Department of Pathology, University of California, San Diego
Hypothesis
Can targeting Oncostatin M and the IL-6 family provide therapeutic benefits for retinal diseases?
Conclusion
Targeting Oncostatin M and the IL-6 family may lead to innovative treatments for retinal diseases by modulating their activity.
Supporting Evidence
- Retinal diseases involve complex processes like inflammation and abnormal blood vessel growth.
- Oncostatin M and IL-6 family cytokines play dual roles in promoting and resolving inflammation.
- Targeting these cytokines could lead to new treatments for retinal diseases.
- Current research indicates that modulating OSM activity may improve outcomes in retinal conditions.
Takeaway
This study looks at how certain proteins can help treat eye diseases that cause vision loss. By understanding these proteins, doctors might find better ways to help people see better.
Methodology
This is a comprehensive review that examines existing research on Oncostatin M and IL-6 family cytokines in retinal diseases.
Limitations
The review does not provide new experimental data and relies on existing studies, which may have varying methodologies and results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website